Theravance to Present at Investor Conferences in November 2012

Theravance to Present at Investor Conferences in November 2012 
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/06/12 --  Theravance,
Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar,
Theravance's Senior Vice President and Chief Financial Officer, is
scheduled to present at the following investor conferences in
November 2012: 
Credit Suisse 2012 Healthcare Conference
 Arizona Biltmore Hotel,
Phoenix, AZ
 Wednesday, November 14, 2012
 8:30 a.m. MST 
Piper Jaffray Healthcare Conference
 The New York Palace, New York,
 Tuesday, November 27, 2012
 8:30 a.m. EST 
All webcast information will be available on Theravance's web site at Listeners are encouraged to visit the site at
least 15 minutes prior to the scheduled presentation to register,
download and install any necessary audio software.  
About Theravance 
Theravance is a biopharmaceutical company with a pipeline of
internally discovered product candidates and strategic collaborations
with pharmaceutical companies. Theravance is focused on the
discovery, development and commercialization of small molecule
medicines across a number of therapeutic areas including respiratory
disease, bacterial infections, and central nervous system (CNS)/pain.
Theravance's key programs include: Relvar(TM) or Breo(TM) (FF/VI),
umeclidinium bromide/vilanterol (UMEC/VI) and MABA (Bifunctional
Muscarinic Antagonist-Beta2 Agonist), each partnered with
GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor
Antagonist program. By leveraging its proprietary insight of
multivalency to drug discovery, Theravance is pursuing a
best-in-class strategy designed to discover superior medicines in
areas of significant unmet medical need. For more information, please
visit Theravance's web site at 
THERAVANCE(R), the Theravance logo, and MEDICINES THAT MAKE A
DIFFERENCE(R) are registered trademarks of Theravance, Inc.  
Relvar(TM) or Breo(TM) (FF/VI) is an investigational medicine and is
not currently approved anywhere in the world. Relvar(TM), Breo(TM)
and Ellipta(TM) are trademarks of the GlaxoSmithKline group of
companies. The use of these brand names has not yet been approved by
any regulatory authority. 
Theravance's presentations will contain certain "forward-looking" 
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995 regarding, among other things,
statements relating to goals, plans, objectives and future events.
Theravance intends such forward-looking statements to be covered by
the safe harbor provisions for forward-looking statements contained
in Section 21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. Examples of such statements
include statements relating to the status and timing of clinical
studies, data analysis and communication of results, statements
regarding the potential benefits and mechanisms of action of drug
candidates, statements concerning the timing of seeking regulatory
approval of our product candidates, statements concerning the
enabling capabilities of Theravance's approach to drug discovery and
its proprietary insights, statements concerning expectations for the
discovery, development and commercialization of product candidates
and projections of revenue, expenses and other financial items. These
statements are based on the current estimates and assumptions of the
management of Theravance as of the date of the presentations and are
subject to risks, uncertainties, changes in circumstances,
assumptions and other factors that may cause the actual results of
Theravance to be materially different from those reflected in its
forward-looking statements. Important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements include, among others, risks related to
delays or difficulties in commencing or completing clinical and
non-clinical studies, the potential that results of clinical or
non-clinical studies indicate product candidates are unsafe or
ineffective, our dependence on third parties in the conduct of our
clinical studies, delays or failure to achieve regulatory approvals
for product candidates, risks of relying on third-party manufacturers
for the supply of our product and product candidates and risks of
collaborating with third parties to discover, develop and
commercialize products. These and other risks are described in
greater detail under the heading "Risk Factors" contained in
Theravance's Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission (SEC) on October 31, 2012 and the risks
discussed in our other period filings with SEC. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. Theravance assumes no obligation to
update its forward-looking statements. 
Contact Information: 
Michael W. Aguiar 
Senior Vice President and Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.